RU2003111175A - Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелия - Google Patents
Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелияInfo
- Publication number
- RU2003111175A RU2003111175A RU2003111175/15A RU2003111175A RU2003111175A RU 2003111175 A RU2003111175 A RU 2003111175A RU 2003111175/15 A RU2003111175/15 A RU 2003111175/15A RU 2003111175 A RU2003111175 A RU 2003111175A RU 2003111175 A RU2003111175 A RU 2003111175A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- ppar
- activator
- composition
- ubiquinone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Композиция, содержащая активатор рецепторов, активируемых пероксисомальным пролифератором (PPAR), выбранный из фибрата, тиазолидиндиона и их фармацевтически приемлемых солей; бензохинон, выбранный из убихинона, предшественника убихинона, способного метаболизироваться в организме человека или животного до указанного убихинона, и их фармацевтически приемлемых солей.
2. Композиция по п.1, отличающаяся тем, что указанный убихинон или его предшественник является коэнзимом Q10 или его предшественником.
3. Композиция по п.1 или 2, отличающаяся тем, что указанный активатор PPAR является фенофибратом.
4. Композиция по п.3, отличающаяся тем, что указанный фенофибрат микронизирован совместно с твердым поверхностно-активным веществом.
5. Композиция по п.4, отличающаяся тем, что указанное твердое поверхностно-активное вещество является лаурилсульфатом натрия.
6. Фармацевтическая композиция, включающая композицию по любому из пп.1-5 совместно с фармацевтически приемлемым носителем или разбавителем.
7. Способ получения фармацевтической композиции, как она определена в п.6, который включает смешивание указанного активатора PPAR и бензохинона с фармацевтически приемлемым носителем или разбавителем.
8. Композиция, содержащая активатор рецепторов, активируемых пероксисомальным пролифератором (PPAR), и бензохинон, по любому из пп.1-5 для использования в терапии.
9. Применение композиции по любому из пп.1-5 для производства медикамента для использования при лечении нарушения, характеризующегося дисфункцией эндотелия.
10. Применение по п.9, отличающееся тем, что указанное нарушение выбрано из группы, состоящей из сердечно-сосудистого заболевания, гипертонии, инсульта, инфаркта миокарда, заболевания периферических сосудов, стенокардии, сердечной недостаточности, диастолической и/или систолической дисфункции желудочков, макро- и микроангиопатии у больных диабетом и повреждения тканей, связанного с ишемией или реперфузией.
11. Применение по п.9 или 10, отличающееся тем, что указанный медикамент имеет форму, адаптированную для введения указанного активатора рецепторов, активируемых пероксисомальным пролифератором (PPAR), и бензохинона раздельно, последовательно или одновременно.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR1038A AUPR103800A0 (en) | 2000-10-26 | 2000-10-26 | Compositions for the treatment of endothelial dysfunction |
| AUPR1038 | 2000-10-26 | ||
| AUPR3424A AUPR342401A0 (en) | 2001-02-28 | 2001-02-28 | Compositions for the treatment of endothelial dysfunction |
| AUPR3424 | 2001-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003111175A true RU2003111175A (ru) | 2004-09-10 |
Family
ID=25646491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003111175/15A RU2003111175A (ru) | 2000-10-26 | 2001-10-23 | Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелия |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7410983B2 (ru) |
| EP (1) | EP1328266B1 (ru) |
| JP (1) | JP4236464B2 (ru) |
| KR (1) | KR100862129B1 (ru) |
| CN (1) | CN1220488C (ru) |
| AR (1) | AR035071A1 (ru) |
| AT (1) | ATE316787T1 (ru) |
| AU (1) | AU2176502A (ru) |
| BG (1) | BG65979B1 (ru) |
| BR (1) | BR0114701A (ru) |
| CA (1) | CA2426625C (ru) |
| CY (1) | CY1105007T1 (ru) |
| CZ (1) | CZ301282B6 (ru) |
| DE (1) | DE60117046T2 (ru) |
| DK (1) | DK1328266T3 (ru) |
| DZ (1) | DZ3442A1 (ru) |
| EE (1) | EE05281B1 (ru) |
| ES (1) | ES2257457T3 (ru) |
| HK (1) | HK1057340A1 (ru) |
| HU (1) | HUP0303566A3 (ru) |
| IL (2) | IL155524A0 (ru) |
| MA (1) | MA25847A1 (ru) |
| MX (1) | MXPA03003733A (ru) |
| NO (1) | NO332260B1 (ru) |
| PL (1) | PL212952B1 (ru) |
| PT (1) | PT1328266E (ru) |
| RU (1) | RU2003111175A (ru) |
| SK (1) | SK287992B6 (ru) |
| TN (1) | TNSN01151A1 (ru) |
| WO (1) | WO2002034259A1 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554500C2 (ru) * | 2013-09-20 | 2015-06-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ лечения ишемического инсульта |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2453147A1 (en) | 2001-07-11 | 2003-01-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
| CA2481371A1 (en) * | 2002-03-11 | 2003-09-18 | Peter Zahradka | Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| US20070225614A1 (en) | 2004-05-26 | 2007-09-27 | Endothelix, Inc. | Method and apparatus for determining vascular health conditions |
| FR2845602B1 (fr) * | 2002-10-11 | 2005-07-08 | Servier Lab | Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
| FR2868313B1 (fr) * | 2004-03-31 | 2008-08-15 | Servier Lab | Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| EP1621200A1 (en) * | 2004-07-26 | 2006-02-01 | Fournier Laboratories Ireland Limited | Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
| EA016226B1 (ru) | 2005-06-01 | 2012-03-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические соединения для лечения митохондриальных заболеваний |
| EP1785133A1 (en) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| US7897326B2 (en) | 2006-03-16 | 2011-03-01 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Peroxisome-proliferator activated receptor-alpha agonists for organ preservation |
| US20070225606A1 (en) * | 2006-03-22 | 2007-09-27 | Endothelix, Inc. | Method and apparatus for comprehensive assessment of vascular health |
| US20080027330A1 (en) * | 2006-05-15 | 2008-01-31 | Endothelix, Inc. | Risk assessment method for acute cardiovascular events |
| US20080081963A1 (en) * | 2006-09-29 | 2008-04-03 | Endothelix, Inc. | Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress |
| KR100989093B1 (ko) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물 |
| JP2012502064A (ja) | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
| EP2391219A4 (en) * | 2009-01-29 | 2013-03-06 | Joshua D Levine | METHOD FOR ADDING VEGETABLE SUBSTANCES / NUTRITIONAL AGGREGATES FOR PHARMACEUTICAL TREATMENT IN A PHARMACOTHERAPEUTIC TREATMENT |
| US8973851B2 (en) | 2009-07-01 | 2015-03-10 | The Procter & Gamble Company | Apparatus and methods for producing charged fluid droplets |
| US8772349B2 (en) * | 2010-03-26 | 2014-07-08 | Vivacell Biotechnology Espana, S.L. | Cannabinoid quinone derivatives |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| WO2019084540A1 (en) | 2017-10-27 | 2019-05-02 | Zeta Biolongevity, Inc. | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PROTEINURY AND ENDOTHELIAL EROSION |
| CN110907407B (zh) * | 2019-12-03 | 2022-02-25 | 东北石油大学 | 一种基于spr的高灵敏度光子准晶体光纤折射率传感器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229385A (en) | 1986-01-30 | 1993-07-20 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
| FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| FI102273B1 (fi) | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö |
| FR2730231B1 (fr) | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| EP1034791A1 (en) | 1997-11-28 | 2000-09-13 | Nikolai Vasilievich Karsanov | Anti-hypoxic and anti-ischemic drug |
| WO2001015593A2 (en) * | 1999-09-02 | 2001-03-08 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
-
2001
- 2001-10-23 AT AT01988586T patent/ATE316787T1/de active
- 2001-10-23 JP JP2002537311A patent/JP4236464B2/ja not_active Expired - Fee Related
- 2001-10-23 CZ CZ20031148A patent/CZ301282B6/cs not_active IP Right Cessation
- 2001-10-23 SK SK508-2003A patent/SK287992B6/sk unknown
- 2001-10-23 EP EP01988586A patent/EP1328266B1/en not_active Expired - Lifetime
- 2001-10-23 RU RU2003111175/15A patent/RU2003111175A/ru not_active Application Discontinuation
- 2001-10-23 WO PCT/EP2001/012425 patent/WO2002034259A1/en active IP Right Grant
- 2001-10-23 IL IL15552401A patent/IL155524A0/xx active IP Right Grant
- 2001-10-23 DZ DZ013442A patent/DZ3442A1/fr active
- 2001-10-23 BR BR0114701-3A patent/BR0114701A/pt not_active Application Discontinuation
- 2001-10-23 AU AU2176502A patent/AU2176502A/xx active Pending
- 2001-10-23 MX MXPA03003733A patent/MXPA03003733A/es active IP Right Grant
- 2001-10-23 PT PT01988586T patent/PT1328266E/pt unknown
- 2001-10-23 CA CA2426625A patent/CA2426625C/en not_active Expired - Fee Related
- 2001-10-23 PL PL361635A patent/PL212952B1/pl not_active IP Right Cessation
- 2001-10-23 KR KR1020037004793A patent/KR100862129B1/ko not_active IP Right Cessation
- 2001-10-23 CN CNB01817972XA patent/CN1220488C/zh not_active Expired - Fee Related
- 2001-10-23 ES ES01988586T patent/ES2257457T3/es not_active Expired - Lifetime
- 2001-10-23 DE DE60117046T patent/DE60117046T2/de not_active Expired - Lifetime
- 2001-10-23 DK DK01988586T patent/DK1328266T3/da active
- 2001-10-23 US US10/399,639 patent/US7410983B2/en not_active Expired - Fee Related
- 2001-10-23 EE EEP200300165A patent/EE05281B1/xx not_active IP Right Cessation
- 2001-10-23 HU HU0303566A patent/HUP0303566A3/hu unknown
- 2001-10-25 TN TNTNSN01151A patent/TNSN01151A1/en unknown
- 2001-10-26 AR ARP010105032A patent/AR035071A1/es unknown
-
2003
- 2003-04-21 IL IL155524A patent/IL155524A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031851A patent/NO332260B1/no not_active IP Right Cessation
- 2003-04-25 MA MA27124A patent/MA25847A1/fr unknown
- 2003-04-25 BG BG107765A patent/BG65979B1/bg unknown
-
2004
- 2004-01-14 HK HK04100253A patent/HK1057340A1/xx not_active IP Right Cessation
-
2006
- 2006-03-21 CY CY20061100400T patent/CY1105007T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554500C2 (ru) * | 2013-09-20 | 2015-06-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ лечения ишемического инсульта |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003111175A (ru) | Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелия | |
| EP1507529B1 (en) | Combination comprising valsartan, amlodipine and hydrochlorothiazide | |
| Kriwisky et al. | Haloperidol-induced torsades de pointes | |
| KR101718639B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| US9622979B2 (en) | Multilayered dosage form | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| ES2315640T3 (es) | Metodo para tratar la insuficiencia cardiaca grave y medicamento para la misma. | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| CA2458981A1 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
| Maruenda et al. | Hypertension in the elderly with coexisting benign prostatic hyperplasia | |
| RU2009101971A (ru) | Галеновый состав алискирена и гидрохлортиазида | |
| ES2367109T3 (es) | Uso de un derivado de amina ciclico específico o sus sales farmacéuticamente aceptables para el tratamiento o la prevención de la insuficiencia cardiaca. | |
| Simon et al. | Comparison of antihypertensive and β1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension | |
| RU2001134298A (ru) | Применение антагонитов кортизола при лечении сердечной недостаточности | |
| NZ534221A (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| SK19332001A3 (sk) | Použitie antagonistov kortizolu v liečení srdcového zlyhania | |
| RU2003130641A (ru) | Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря | |
| Porcellati et al. | Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension | |
| CN100423728C (zh) | 一类用于治疗各种同心脏血供相关的疾病的复方药 | |
| RU2004137109A (ru) | Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда | |
| CN1354676A (zh) | 用于心血管疾病疗法的氨基四氢化萘衍生物 | |
| JP5982715B2 (ja) | 抗高血圧薬組成物 | |
| Hansson | Reversal of cardiac and vascular hypertrophy by antihypertensive therapy | |
| McCarthy et al. | A placebo-controlled crossover study of ketanserin in elderly hypertensive patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050111 |